An Open-label, Non-randomized, 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment With Belimumab 10 mg/kg in Systemic Lupus Erythematosus Subjects
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接:
https://search.vivli.org/doiLanding/studies/PR00007831/isLanding
下载链接
链接失效反馈官方服务:
资源简介:
This study will assess the effect of a 24-week withdrawal followed by a 28-week
reintroduction of belimumab 10 mg/kg plus standard of care medications in subjects with
stable low systemic lupus erythematosus (SLE) disease activity. Rebound phenomenon will be
assessed for subjects who have permanently withdrawn from further belimumab treatment.
提供机构:
Vivli
创建时间:
2022-04-25



